Objective. To examine whether the RA MRI score (RAMRIS) for RA of the wrist/hand meets the OMERACT filter criteria-truth (validity), discrimination and feasibility.
Introduction
RA is a systemic autoimmune disease, characterized by persistent or recurring synovitis that is often associated with substantial joint damage and disability [1] . Pharmaceutical developers and regulatory agencies place a high value on labelling that presents strong evidence for limitation of joint damage [24] . Sharp scoring of hand and foot radiographs is considered the reference standard for assessment of joint damage. However, Sharp scores are relatively unable to detect worsening erosions and joint space narrowing (JSN) over short periods [requiring randomized controlled trials (RCTs) of 512 months duration] [25] . To reliably detect the efficacy of novel treatments that limit joint damage, sensitive methods that measure joint inflammation and structural damage are essential.
Periodic evaluation of MRI in studies over 36 months has detected effects of treatments on both joint inflammation and damage [68] . Recent draft updates to the Food and Drug Administration (2013) and European Medicines Agency (November 2011) guidance documents acknowledge that MRI measures might be useful for evaluating RA joint damage in RCTs; however, they indicated that MRI methods are not sufficiently validated [3, 4] .
We performed a systematic literature review (SLR) to determine the state of validation of MRI measurement methods. Each identified method was evaluated according to the OMERACT filter: truth (face, criterion, content and construct validity), discrimination and feasibility [911] .
Methods

Search strategy
To identify validated MRI measurement methods for RA, we conducted an SLR consistent with Preferred Reporting Items for Systematic Reviews and Meta-analyses methodology. Our initial search (19702011) in PubMed with Cochrane hedge, used the terms: RA, AND MRI, AND specific terms: for example, synovitis, JSN, erosions, osteitis or bone marrow oedema (BMO) AND humans AND RCTs, clinical studies. Based on the results demonstrating that RAMRIS was the only method with validation data, we updated our search adding RAMRIS to the search terms to July 2011 to July 2014. We also examined bibliographies of the ultimately selected articles. For the update, we used the same search strategy in Scopus prior to finalizing this review (see Search Strategy for RA Imaging Markers, available at Rheumatology Online).
Article identification and evaluation
Independent pairs of authors evaluated the titles and abstracts using the following criteria: RA patients 518 years of age; MRI performed as part of a clinical study; 510 patients; and English. We excluded reviews, abstracts and letters to the editor. Prior to initiating the selection process, author pairs achieved a 95% consistency for article identification. Consensus for any disagreements was achieved by discussion among the authors.
Level of evidence was determined using the modified Cochrane Back Review Group criteria [12] : highest level: single/multicentre (RCTs) describing 1.5 T MRI acquisition and scoring together with statistical analyses and sufficient clinical, laboratory and/or radiographic data to examine validity; moderate level: single-centre RCTs and longitudinal observational studies (LOSs) with cohort size 510, and/or limited description of MRI and/or scoring method or/and statistical method, and/or clinical data; low level: articles with less than moderate evidence were rejected. We limited our selection to articles describing results with 1.5 T MRI, since image quality with low-field MRI is evolving. Articles describing criterion validity (e.g. histopathology, multiparameter/micro-CT) for at least one MRI feature were also included, regardless of cohort size).
Data extraction
Each author extracted identified articles using a standardized form, entering data for MRI field strength, acquisition method and sequences, use of gadolinium (Gd), study design, patient characteristics, measurement method(s) and statistics used with clinical, laboratory and radiographic data associated with the measure [911] ( Table 1) . To be included, an article had to contain at least one validity criterion for at least one MRI-assessed feature.
Analysis and reporting methods
Descriptions of each type of validity data were tabulated by study. To optimize our ability to identify MRI measurement methods with adequate validity data, we enumerated the number of studies using each method. To examine content validity, age range, RA duration, erosions, RF and ACPA status were recorded for each study. Intra-and inter-class correlations (ICCs) and kappa statistics were included to describe the reliability of the measure, together with Spearman's correlation coefficients examining relationships to clinical data. Wilcoxon's rank sum test was also used to evaluate sensitivity to change and discrimination. Image acquisition and scoring data were tabulated when available to assist in estimating feasibility.
Results
A total of 634 titles and abstracts were examined, and 202 articles were extracted: 92 included at least 1 MRI measurement method and at least 1 validity criterion. Since RAMRIS was the only consistently used method, analysis was limited to studies reporting data to determine the validity, sensitivity to change/responsiveness, discrimination and feasibility of RAMRIS. The majority of studies reported RAMRIS measurement for 1.5 T MRI images (26 articles between 1999 and June 2014). There are 10 RCTs, 6 LOSs, 7 cross-sectional studies and 1 validation study, as well as 2 that examined criterion validity. No articles explicitly examined aspects of face validity. Seventeen articles reported use of RAMRIS in low-field MRI studies but were not included, as image quality and reliability of measurement have been evolving (see Figure 1 ).
Criterion validity
Four articles provided moderate to high-level evidence for 1.5 T imaging criterion validity of synovitis, osteitis/BMO and/or erosions ( Table 2 ). Based on histopathology of an inflamed RA joint visualized on MRI before the specimen was obtained, there were correlations with abnormalities as follows: one for synovitis/JSN [13] , two for osteitis [14, 15] and one for erosions [15] . Micro-CT studies comparing CT erosions to MRI erosions were also accepted.
Synovitis
Ostendorf et al. [13] reported synovitis histopathology for second MCP miniarthroscopy within 24 h of 1.5 T MRI with dynamic contrast enhancement. MRI synovial vascularity and proliferation correlated with synovial hyperaemia and thickening on miniarthroscopy, respectively (P = 0.0038; P = 0.0063). Bony changes by miniarthroscopy correlated with JSN on MRI (P = 0.0015).
Osteitis
Bone marrow oedema (BMO-called osteitis throughout the rest of this article) seen on MRI correlated with histopathology of those lesions in total joint replacement specimens [14, 15] . In 4 patients and 7 bones, McQueen et al. [14] examined MRI pre-surgery vs histological evaluation at orthopaedic surgery. High-grade MRI bone oedema was strongly associated with histology showing an inflammatory infiltrate consistent with osteitis. Similar findings were reported by Jimenez-Boj et al. [15] for lesions identified on 1.5 T MRI without Gd enhancement. 
Erosions
Multiparameter CT and microCT are recognized to be especially sensitive for identification of bony abnormalities (Table 2) . Albrecht et al. [16] reported that MRI-visualized erosions were readily seen with CT or microCT [16] .
Is RAMRIS scoring of 1.5 T MRI images of the RA hand/wrist valid, and does it meet the OMERACT filter?
OMERACT methods development conferences for RAMRIS were held in 2000, 2004 and 2008, and two atlases were published in 2005, standardizing RAMRIS and documenting that experts agree on the features to be measured, providing evidence of face validity [1722] ( Table 3 ). An overview of the numbers of articles that show how RAMRIS meets the OMERACT filter criteria is provided by category in Table 4. Supplementary Tables  S13, available Tables S13, available at Rheumatology Online).
Construct validity
Construct validity includes convergence, correlations with clinical and laboratory results that measure joint inflammation (e.g. synovitis and osteitis with ESR, CRP, DAS28, etc.) or damage (e.g. RAMRIS erosions correlates with HAQ-DI). It also includes discriminant or divergent validity (e.g. no correlation would be expected between RAMRIS synovitis and osteitis scores and DAS remission). For predictive validity, RAMRIS measures should correlate with subsequent joint damage such as the van der Heidje modified Sharp radiographic scores (vdHSSs) ( Table 4 and supplementary Tables S13, available at Rheumatology Online).
Convergent vs divergent (discriminant) construct validity
Synovitis
Six studies support convergent construct validity, demonstrating RAMRIS synovitis correlations with ESR, DAS28, HAQ-DI and ACR response [r = 0.210.6 (P < 0.05)] [6, 8, 26, 27, 30, 31] . Three studies reported lack of correlations between RAMRIS synovitis and HAQ-DI, DAS28 remission and ACR remission (P = 0.220. 60 
Erosions
One study supported construct validity for RAMRIS erosions, describing correlations with DAS28 and CRP (Spearman's r = 0.23; P < 0.001) [8] , while another study, using DAS28/CRP/ESR, showed no such correlations (P = 0.160.46) [21] . As with osteitis, no correlations were found in DMARD-IR patients [8] .
Predictive construct validity
For predictive construct validity for 1.5 T MRI, McQueen et al. [21] demonstrated that a preliminary BMO/osteitis score predicted the 6-year total Sharp X-ray score (hands and feet, P = 0.01).
Synovitis/osteitis/erosions
Three studies correlated vdHSS-based radiographic progression with RAMRIS synovitis (Spearman's r = 0.250. 
Reliability and reproducibility
Inter and intra-reader consistency (reliability) and reproducibility (repeatability of measurement in short time frame, or/and by more than one observer) was assessed in a range of articles-RCTs, LOSs, cross-sectional studies, as well as one validation study. Overall, reliability and reproducibility were good to excellent (Table 4 and supplementary Tables S13, available at Rheumatology Online).
Synovitis
The measurement of synovitis was reliable and reproducible. In 12 articles, the intra-rater ICCs were (0.770.98) and kappa (k) statistics were (0.810.88) [6, 7, 26 
Sensitivity to change
Sensitivity to change describes the difference between two time points within a treatment or population, independent of differences between treatments (see change in statistics described in supplementary Tables S1S3 available at Rheumatology Online).
Synovitis
Data for sensitivity to change for the RAMRIS synovitis measurement was provided in 14 studies: 4 LOSs, 9 RCTs and 1 validation study. The time points analysed were 46, 1218, 24 and 5254 weeks. Significant change was seen in two single-centre RCTs after only 46 weeks of treatment: one evaluating a TNFi, and one evaluating double-filtration plasmapheresis (DFPP) [26, 42] . Four other TNFi studies demonstrated synovitis improvement in 1218 weeks. One example is a study of infliximab vs MTX in which median (min, max) synovitis decreased, respectively, by À7 (À12, 1) and À1 (À4, 2), (P = 0.0030.05) [32, 34, 4345] . Other studies showed improvement after 5254 weeks [4547] .
Osteitis
Similar to synovitis, seven RCTs described change in RAMRIS osteitis at time points ranging from 4 to 54 weeks. The majority of RCTs evaluated TNFi treatment vs MTX while patients were on background DMARDs.
In one study with infliximab, a significant decrease in osteitis was already seen at week 4, and confirmed at week 16 [43] . In another four TNFi RCTs, the change was seen at 1218 weeks, and in two golimumab RCTs changes were seen at 24 weeks, P < 0.001 [35, 37] . In two other infliximab studies there was significant reduction in osteitis-median (min, max): À9 (À25, 5) (P < 0.05) at 52À54 weeks [46, 47] . However, significant osteitis change was not seen at 6 weeks in two other TNFi studies [26, 27] or with DFPP (P = 0.18) [42] . In an abatacept trial, a decrease in osteitis of À1.94 (0.86) was seen with abatacept/MTX at 18 weeks [23, 32] . In a MRI measurement validation study reporting 1-year change detected with RAMRIS in four early RA (ERA) and six established RA (estRA) patients by multiple readers, the smallest detectable difference at 12 months for osteitis was 2.73 (ERA), and 3.68 for established RA patients [36] .
Erosions
While erosions are seen on MRI with higher sensitivity compared with X-ray, change in RAMRIS erosions has not been consistently shown. Although effects to limit worsening may be discernible at 24 weeks with RAMRIS and vdHSSs, healing is not readily demonstrable with these methods, raising questions about the effects of treatment vs measurement methods. The magnitude of change/absence of change at 654 weeks in nine RCTs and five LOSs was <1% of the range and independent of disease duration, present or prior treatment/response and Table S3 , available at Rheumatology Online). RAMRIS erosions did not change statistically in 6 weeks in two studies [26, 27] or in 12À18 weeks in seven studies [6, 7, 21, 23, 30, 33, 35] . There is some inconsistency at 3, 6 and 12 months in LOSs [6, 7, 25, 38] . In two LOSs, changes were discernible at 12 weeks, whereas in two others there were no detectable changes [6, 38] . For the studies discerning changes, the standardized response means were >0.23À0.32, and the patients had either early or established disease with high disease activity [6] .
At 24 weeks, three RCTs and one LOS found small changes [6, 23, 35, 42, 45] , whereas in one RCT and three LOSs no change was seen [7, 25, 33] . For example, in a denosumab RCT, an increase in RAMRIS erosions at 24 weeks was detected in all three arms, but was 0.06/0.13/ 1.75 U high-dose vs low-dose vs placebo [41] .
Even at 52 weeks, RAMRIS did not detect a change in erosions consistently. Of seven studies (three RCTs and four LOSs [6, 7, 25, 37, 41, 43, 45] , in only three were there changes in RAMRIS erosions [6, 38, 42] .
Discrimination: does RAMRIS differentiate efficacy between therapies?
Discrimination refers to the ability to differentiate between therapies. Among nine RCTs, discrimination using synovitis and osteitis was usually seen by 1218 weeks. In contrast, RAMRIS erosions were discriminating at 2452 weeks (occasionally at 1218 weeks) (see statistics described in supplementary Tables S13, available at Rheumatology Online).
Synovitis
Six of nine RCTs provide evidence that change in RAMRIS synovitis can discriminate between treatments at all time points. Some change in RAMRIS synovitis is seen as early as 6 weeks following initiation of a TNFi, and consistently at 12 weeks [23, 26, 27, 30, 32, 34, 42, 43, 45] . In golimumab studies in estRA and ERA patients, differences in synovitis could be discriminated at 12 weeks, and the mean (S.D.) change in estRA was À1.77 (2.54) and in ERA, À1.92 (3.09), compared with placebo, À0.15 (2.75) and +0.14 (2.98), respectively (P < 0.001 in both studies) [33, 35] . By 24 weeks RAMRIS synovitis was consistently able to be discriminated in all studies [23, 26, 27, 30, 32, 34, 42, 43, 45] . For example, DFPP was able to be discriminated from control with a median difference of 7 by RAMRIS (P < 0.001) [48] .
Osteitis
None of three RCTs evaluating either TNFi or DFPP reported reduced osteitis vs control at 4À6 weeks [48, 26, 27] . In six of seven RCTs, RAMRIS osteitis was able to discriminate between active treatment and placebo at 1218 weeks [24, 30, 33, 35, 45, 44] . A single study of a SyK inhibitor (SyKi) was not able to discriminate between active treatment and placebo. RAMRIS osteitis changes were À0.2 (SyKi) vs +1.2 (control) (P = 0.058) [30] .
Change in RAMRIS osteitis measured at 24 and 52 weeks in five RCTs could consistently discriminate between the experimental agent and the control [32, 35, 45, 44, 48] .
Erosions
Discrimination was evaluable in nine RCTs at time points across 654 weeks. The majority of RCTs examined change in erosions with TNFi treatment in patients while on background DMARDs.
Differences in RAMRIS erosions scoring did not discriminate at 6 weeks [26, 27] and were inconsistent at 1218 weeks (two studies showed discrimination and two did not) [21, 30, 33, 35, 44] . At 24 weeks discrimination was generally achieved. In a TNFi study in MTX-naïve patients, the mean change (S.D.) reported for TNFi vs placebo was À0.40 
Feasibility
We could not find specific data on the day-to-day issues of feasibility, neither time to perform MRIs, to quality assure images, nor importantly, the cost of these key activities. Nevertheless, there is good evidence from RCTs that MRIs have been done on all continents and in several multicentre studies. Thus, while feasible in dedicated centres during adequately funded clinical trials, based on the fact these studies have been done, feasibility outside that venue has not been examined.
Discussion
This SLR represents a critical examination of the published data regarding the state of validation of RAMRIS scoring of the hands and wrists in RA. It provides evidence for the validity of RAMRIS for measurement of synovitis and osteitis, in the hands/wrists of RA patients treated in clinical trials. Further, these data describe RAMRIS responsiveness and sensitivity to change together with evidence that RAMRIS can discriminate efficacy among therapies. Specific data demonstrating feasibility for clinical use were not found, but evidence for utility to assess whether an intervention limits joint inflammation and damage in well-controlled clinical trials appears sufficient to apply RAMRIS measures as end points.
Three prior reviews examined the validity and usefulness of RAMRIS. In 2008, Hodgson et al. briefly described the state of RAMRIS validation, and observed that reliability and discriminatory validity of scoring remained to be verified [4953] . In 2010, Suter et al. [54] reported an SLR using Cochrane methods to specifically examine the role of MRI in the diagnosis and prognosis of ERA and showed its ability to predict later radiographic damage, but they did not examine validity. Our SLR extends the earlier results, by presenting validation evidence not previously described, which supports many of the recommendations of the 2013 ACR Clinical Trials Task Force Imaging Group and OMERACT Inflammatory Arthritis Working Group article advocating RAMRIS measurement in clinical trials [55] .
Following on the ACR Task Force report, this SLR further documents the ability of RAMRIS measures to discriminate between treatments, including only four of the same studies [23, 30, 32, 34, 41 ] that have applied RAMRIS measures for synovitis, BMO/osteitis and/or erosions. We identified 10 published RCTs [23, 26, 27, 30, 32, 34, 41, 42, 45, 48 ] that reported at least 1 RAMRIS measure and used high-field MRI, only 8 of which reported data for all 3 RAMRIS measures [23, 26, 27, 30, 32, 34, 45, 48] . Importantly, not all measures perform consistently in these studies.
Sensitivity to change and responsiveness are strongly supported for RAMRIS synovitis and osteitis, which improves within 1218 weeks with potent treatments. Further, changes in RAMRIS synovitis and osteitis usually discriminate between treatments in this time frame [30, 35, 45, 33, 44, 48] . Importantly, in terms of detecting clinical benefit, high RAMRIS synovitis and osteitis predicted subsequent radiographic joint damage, and improvements predicted limitation of damage [68, 56] .
In contrast, for erosions, sensitivity to change is largely detected as worsening, so that limitation of damage with improvement in synovitis and osteitis results in smaller changes and in a minority of patients, even at 24 weeks and beyond. Although, in one of the RCTs using a RAMRIS erosion end point [34], discrimination was seen at 12 weeks in MTX-naïve patients treated with golimumab/MTX, in four other studies at least 2452 weeks were required to discriminate treatment efficacy [34, 41, 43, 45] .
Thus, examination of whether RAMRIS erosion scoring meets the OMERACT filter is challenging because current treatment recommendations quickly and effectively limit erosions measured by vdHSSs of hand/feet radiographs. Worsening of erosions is seen in only a small minority of patients, and improvement is uncommon, with changes typically small at the group level.
Of particular importance, and not previously carefully examined, the time to improvement is different for different features of joint damage and inflammation assessed by RAMRIS. Some of the differences may derive from patient population and/or sample size, as well as by study design, when measures are taken at different times (e.g. at 6, 12, 18, as well as at 24 weeks vs only at 24 weeks or only at 5254 weeks). RAMRIS synovitis scores decreased as early as 46 weeks. These rigorously conducted studies also reported smallest detectable differences, minimal clinical differences and standardized response means [26, 27, 35, 42] . Significant improvement in osteitis was seen by 1218 weeks and occasionally 24 weeks with various biologics with or without MTX background therapy [23, 26, 27, 30, 32, 42, 43, 45] .
These findings provide useful data for the preparation and conduct of studies designed to guide decisions regarding future development of novel RA treatments. The magnitude, variability, and time to observed changes in RAMRIS synovitis and osteitis are reasonably characterized, and we believe they may be used as end points in studies of 34 months duration. If a trial design requires erosions as an end point, studies of 612 months may be required.
Limitations
The results described here are based only on published studies in peer-reviewed journals, and only those published in English. Potentially relevant data not yet published (e.g. studies reported in recent abstracts and presentations) are not included [5] . In addition, some inevitable heterogeneity was introduced because there is variability in selection of the hand and/or wrist imaged (right/left, dominant/non-dominant), MRI acquisition (e.g. standardization of positioning, quality control of images), and importantly, whether contrast was used to assess inflammation.
Further, to fully substitute for radiographic vdHSSs in studies aimed at regulatory approval and labelling for novel treatments, a measure for JSN is desirable. While there are at least three JSN measures proposed for RAMRIS, consensus and validation have not been achieved thus far [5, 34, 46, 57] . There is also ongoing research for future inclusion of tenosynovitis to strengthen the measurement of joint inflammation within RAMRIS [37, 47, 58, 59] .
Since completion of our search and analysis, two articles describing RCTs using 1.5 T RAMRIS end points and included in the ACR Task Force report have been published [60, 61] . The data further validate these results, and also provide additional evidence of feasibility.
Further, we could not fully address feasibility in quantitative terms as none of the articles reported costs of equipment and standardized acquisition, nor any information regarding patient burden. The requirement for i.v. contrast (Gd) to accurately measure synovitis likely impacts feasibility significantly [40] .
Conclusions
This SLR provides evidence that RAMRIS measurement of synovitis, osteitis and erosions meets the OMERACT filter for use in RA clinical trials evaluating 1.5 T MRI images of RA hand/wrist. However, timing of the measurements to meet validation criteria is variable. Importantly, data from published RCTs provide evidence that RAMRIS measures are responsive and can generally discriminate efficacy between treatment groups within 1218 weeks. Since changes in erosions are small, 2452 weeks are usually necessary for discrimination of effective treatment. Periodic systematic evaluation and standardization to optimize image quality and scoring precision appear necessary for assuring optimal RAMRIS performance.
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